Theriva™ Biologics Reports Third Quarter 2024 Operational Highlights and Financial Results

Target patient enrollment of 92 evaluable patients achieved in the VIRAGE Phase 2b clinical trial of VCN-01 in patients with metastatic pancreatic ductal adenocarcinoma